Press Releases

Date Title and Summary Additional Formats
Toggle Summary Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2019 Financial Results on July 16, 2019
BOTHELL, Wash. --(BUSINESS WIRE)--Jul. 2, 2019-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter 2019 financial results on Tuesday, July 16, 2019 after the close of financial markets. Following the announcement, management will host a conference call and
View HTML
Toggle Summary Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the Congress of the European Hematology Association (EHA) and the International Conference on Malignant Lymphoma (ICML)
-Data Presentations Highlight Continued Advances in Research for Treating Blood Cancers- BOTHELL, Wash. --(BUSINESS WIRE)--Jun. 12, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced data from its ADCETRIS ® (brentuximab vedotin) clinical development program at the 24 th Annual Congress of
View HTML
Toggle Summary Seattle Genetics’ Antibody-Drug Conjugate Technology Utilized in Genentech’s Polivy, Now Approved by FDA
-Approval Triggers Milestone Payment and Royalties on Worldwide Net Sales- BOTHELL, Wash. --(BUSINESS WIRE)--Jun. 10, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced U.S. Food and Drug Administration ( FDA ) approval of Polivy™ (polatuzumab vedotin-piiq), which is an antibody-drug
View HTML
Toggle Summary Seattle Genetics Announces Additional Analyses of ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials of ADCETRIS® (Brentuximab Vedotin) at the 2019 ASCO Annual Meeting
Three-Year Update of ECHELON-1 Trial Continues to Demonstrate Superior Clinical Activity of ADCETRIS in Combination with Chemotherapy when Compared to ABVD in Frontline Hodgkin Lymphoma Analyses Describe ADCETRIS Activity in T-Cell and B-Cell Non-Hodgkin Lymphomas Across All Levels of CD30
View HTML
Toggle Summary Seattle Genetics and Astellas Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer
- First Investigational Therapy in a Pivotal Trial to Address Unmet Need for Patients with Advanced Urothelial Cancer After Treatment with Platinum Chemotherapy and a PD-1 or PD-L1 Inhibitor- -Data Featured in Official Press Program and Presented in Late-Breaking Oral Session Today at 2019 ASCO
View HTML
Toggle Summary Seattle Genetics Appoints Robin Taylor, Ph.D., Chief Commercial Officer
BOTHELL, Wash. --(BUSINESS WIRE)--May 21, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the appointment of Robin G. Taylor , M.B.A., Ph.D., as Chief Commercial Officer. Dr. Taylor brings 18 years of biotechnology and pharmaceutical company experience in the commercialization of
View HTML
Toggle Summary Seattle Genetics Announces Presentations of New Clinical Data from Multiple Studies of Novel Targeted Therapies at the American Society of Clinical Oncology (ASCO) Annual Meeting
First Presentation of Data from EV-201 Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer Featured in an Oral Session on Monday, June 3 rd BOTHELL, Wash. --(BUSINESS WIRE)--May 15, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced data from six of its
View HTML
Toggle Summary Seattle Genetics to Present at RBC Capital Markets 2019 Global Healthcare Conference
BOTHELL, Wash. --(BUSINESS WIRE)--May 15, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the RBC Capital Markets 2019 Global Healthcare Conference on Wednesday, May 22, 2019 at 8:30 a.m. Eastern Time . The presentation will be webcast live and available
View HTML
Toggle Summary Seattle Genetics Announces Progress in Expanding ADCETRIS® (Brentuximab Vedotin) Indications in Canada
-Health Canada Approves ADCETRIS in Combination with AVD Chemotherapy for the Treatment of Previously Untreated Hodgkin Lymphoma Based on Positive Phase 3 ECHELON-1 Clinical Trial Results- -Supplemental New Drug Submission Completed for ADCETRIS in Combination with CHP Chemotherapy in Frontline
View HTML
Toggle Summary Seattle Genetics Reports First Quarter 2019 Financial Results
-ADCETRIS ® (Brentuximab Vedotin) Net Sales in U.S. and Canada Were $135.0 Million in the First Quarter, an Increase of 42 Percent Over the First Quarter of 2018- -Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer Support Planned
View HTML